<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392948</url>
  </required_header>
  <id_info>
    <org_study_id>25/10/2017</org_study_id>
    <nct_id>NCT03392948</nct_id>
  </id_info>
  <brief_title>PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy</brief_title>
  <acronym>PERSEO</acronym>
  <official_title>PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Society of Invasive Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Society of Invasive Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires
      chronic anticoagulant therapy due to atrial fibrillation or other clinical entities. There
      are many possible different combinations of the antithrombotic therapy after stent
      implantation in these patients.

      Aim of this observational study is to evaluate the real world antithrombotic treatment in
      patients requiring anticoagulant therapy undergoing stent implantation and to compare the
      clinical outcome of patients treated with new oral anticoagulant drugs compared to warfarin.

      The study is prospective, performed in different Italian hospitals and aimed to enroll 1080
      patients with a 1 year follow up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires
      chronic anticoagulant therapy due to atrial fibrillation or other clinical entities. These
      patients pose particular problems when undergo percutaneous coronary intervention with stent
      implantation (PCI-S), because of the different antithrombotic and oral anticoagulant (OAC)
      strategies required after the procedure when dual antiplatelet therapy is recommended.
      Consequently, this scenario requires careful consideration balancing bleeding, stroke and
      acute coronary syndrome risks.

      New oral anticoagulants (NOAC) have been compared to warfarin for stroke prevention in the
      setting of atrial fibrillation and all these drugs showed a similar or improved efficacy over
      warfarin in term of ischemic events as well as bleeding complications reduction. In
      particular, an important safety issue is the reduction of intracranial bleeding compared to
      warfarin. Currently, four different NOAC have been approved for the treatment of patients
      with atrial fibrillation: apixaban, edoxaban, rivaroxaban and dabigatran. The first three
      drugs are anti Xa inhibitors whereas the last one is a direct thrombin inhibitor.

      Data regarding the combination of NOAC and antiplatelet therapy after PCI-S in patients
      requiring chronic anticoagulant therapy are currently scarce.

      The aim of our study is to perform a prospective, multicenter, observational, controlled
      study on patients requiring chronic anticoagulant treatment with either vitamin K antagonists
      or NOAC undergoing PCI-S for concomitant coronary disease.

      The primary objectives of the study are:

        1. To describe the contemporary antithrombotic management during and post PCI-S in patients
           treated with oral anticoagulant therapy

        2. To evaluate, in this context, the efficacy and safety of the different NAOC compared to
           warfarin regimens.

      According to the observational design of the study, anticoagulant therapy (vitamin
      antagonists or new oral anticoagulant drugs), other pharmacological therapy as well as
      procedural device utilized, before, during the procedure and at follow-up will be left to the
      physician decision.

      The events will be adjudicated by a clinical event committee (CEC) comprised of qualified
      physicians. The CEC is responsible for adjudicating all potential endpoint events, including
      death, bleeding, myocardial infarction, stent thrombosis, stroke, and coronary
      revascularization
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>13 Months</target_duration>
  <primary_outcome>
    <measure>Net Adverse Clinical Event</measure>
    <time_frame>1 year</time_frame>
    <description>major bleeding, myocardial infarction, death, stroke, myocardial revascularization</description>
  </primary_outcome>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <condition>Chronic Stable Angina</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic disease requiring oral anticoagulant therapy (atrial fibrillation,
        prosthetic valves, previous pulmonary embolism, venous thrombosis) undergoing either
        elective, urgent or emergency percutaneous coronary interventions with stent implantation
        for acute or chronic coronary disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing percutaneous coronary interventions with stent and an
             indication for chronic anticoagulant therapy.

        Exclusion Criteria:

          -  Patients of age &lt; 18 years old

          -  Lack of written informed consent to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Sciahbasi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Sandro Pertini, ASL RM2, Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Sciahbasi, MD</last_name>
    <phone>3472968314</phone>
    <phone_ext>+39</phone_ext>
    <email>alessandro.sciahbasi@fastwebnet.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Rubboli, MD</last_name>
    <phone>335477354</phone>
    <phone_ext>+39</phone_ext>
    <email>andrearubboli@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria &quot;Mater Domini&quot;</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro CI Indolfi, MD</last_name>
      <phone>09613647151</phone>
      <phone_ext>+39</phone_ext>
      <email>indolfi@unicz.it</email>
    </contact>
    <contact_backup>
      <last_name>Salvatore SD De Rosa, MD, PhD</last_name>
      <phone>3398004776</phone>
      <phone_ext>+39</phone_ext>
      <email>saderosa@unicz.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS Annunziata</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido GP Parodi, MD</last_name>
      <phone>3880451303</phone>
      <phone_ext>+39</phone_ext>
      <email>parodiguido@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe GT Talanas, MD</last_name>
      <phone>3880451303</phone>
      <phone_ext>+39</phone_ext>
      <email>giuseppe.talanas@aousassari.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Vito Fazzi&quot;</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dionigi DF Fischetti, MD</last_name>
      <phone>3471928024</phone>
      <phone_ext>+39</phone_ext>
      <email>dionigi.fischetti@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sandro Pertini</name>
      <address>
        <city>Roma</city>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro AS Sciahbasi, MD</last_name>
      <phone>3472968314</phone>
      <phone_ext>+39</phone_ext>
      <email>alessandro.sciahbasi@fastwebnet.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro AS Sciahbasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis. 2007 May;18(3):193-9.</citation>
    <PMID>17429293</PMID>
  </reference>
  <reference>
    <citation>Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, Smith SC Jr, Peterson ED, Becker RC. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008 Feb;155(2):361-8. doi: 10.1016/j.ahj.2007.09.003. Epub 2007 Oct 25.</citation>
    <PMID>18215609</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 Dec 3;339(23):1665-71.</citation>
    <PMID>9834303</PMID>
  </reference>
  <reference>
    <citation>ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903-12.</citation>
    <PMID>16765759</PMID>
  </reference>
  <reference>
    <citation>Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.</citation>
    <PMID>27567408</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.</citation>
    <PMID>19717844</PMID>
  </reference>
  <reference>
    <citation>Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.</citation>
    <PMID>21830957</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</citation>
    <PMID>21870978</PMID>
  </reference>
  <reference>
    <citation>Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.</citation>
    <PMID>24251359</PMID>
  </reference>
  <reference>
    <citation>Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, Sundström J. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34(22):1670-80. doi: 10.1093/eurheartj/eht049. Epub 2013 Mar 6. Review.</citation>
    <PMID>23470494</PMID>
  </reference>
  <reference>
    <citation>Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.</citation>
    <PMID>27959713</PMID>
  </reference>
  <reference>
    <citation>Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L, Briguori C, Calabrò P, Palmieri C, Rizzi A, Imperadore F, Sangiorgi GM, Valgimigli M, Carosio G, Steffenino G, Galvani M, Di Pasquale G, La Vecchia L, Maggioni AP, Bolognese L; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol. 2014 Nov;26(11):563-9.</citation>
    <PMID>25363997</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4.</citation>
    <PMID>15842354</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>prosthetic valves</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>venous thrombosis</keyword>
  <keyword>percutaneous coronary interventions</keyword>
  <keyword>chronic anticoagulant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make Individual Participant Data available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

